Vanda Gains Fanapt Rights from Novartis for the U.S. Region - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:30PM CST
Vanda Pharmaceuticals Inc. (VNDA) recently announced that it has reached a settlement agreement with Novartis AG (Novartis) related to Fanapt.
BIIB: 340.89 (+5.13), VNDA: 14.69 (+1.11), SHPG: 209.29 (+0.07), NVS: 93.91 (+0.66)
Keryx (KERX) Launches Renal Drug Auryxia in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:35PM CST
Keryx Biopharmaceuticals, Inc. (KERX) announced it has begun to ship Auryxia (ferric citrate) tablets to wholesalers in the U.S.
AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), SCMP: 13.75 (+0.44), KERX: 14.00 (+0.20)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
NPS Pharmaceuticals and Shire Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:30PM CST
A report from Bloomberg indicated that the Shire is considering a potential acquisition of the NPS Pharma.
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18), ABBV: 66.21 (+1.86)
Tax Inversions Wrap Up
NYU Finance Society - at Seeking Alpha - Thu Dec 18, 2:01PM CST
By Karan Magu of NYU Finance Society There has been a recent surge in anti-tax inversion legislation discouraging companies attempting to shift corporate subsidiaries or headquarters to low-tax or tax-free countries. The issue was subjected to a...
AZN: 70.44 (+0.26), SHPG: 209.29 (+0.07), PFE: 31.42 (-0.03), ABBV: 66.21 (+1.86)
NPS Pharmaceuticals (NPSP) Jumps: Stock Moves 18.5% Up - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 7:51AM CST
NPS Pharmaceuticals, Inc. (NPSP) was a big mover last session, as its shares rose almost 19% on the day.
SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18)
Why NPS Pharmaceuticals, Inc. Stock Lifted Off in Midday Trading
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 17, 1:30PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NPS Pharmaceuticals , a biopharmaceutical...
SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18), ABBV: 66.21 (+1.86)
NPS Pharma up 20% on takeover buzz
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 10:21AM CST
SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18)
Better Big Pharma Spinoff: Zoetis Inc. or AbbVie Inc.?
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 17, 8:15AM CST
We're approaching two years after Abbott Labs spun off its pharmaceutical division AbbVie and a little less since Zoetis , Pfizer 's animal health division, separated from its patent company. Seems like a good time to see which spinoff...
ZTS: 43.84 (+0.87), ABT: 45.70 (-0.02), SHPG: 209.29 (+0.07), PFE: 31.42 (-0.03), ABBV: 66.21 (+1.86)
Why the Earnings Streak Will Continue for Shire plc (SHPG) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 7:52AM CST
Shire plc (SHPG) has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports
SHPG: 209.29 (+0.07)
Billionaires Are Loading Up On These 3 Stocks
Patrick Morris, The Motley Fool - Motley Fool - Tue Dec 16, 12:46PM CST
The numbers are in for what the 10 largest hedge funds in America have been buying, letting us see which three companies had the most wanted stock in the third quarter. According to the latest data from S&P Capital IQ and its Hedge Fund...
ACT: 254.20 (-1.68), SHPG: 209.29 (+0.07), ABBV: 66.21 (+1.86), BABA: 105.95 (+0.43)
BioTime Appoints Angus C. Russell to Board of Directors
Business Wire - Mon Dec 15, 7:38AM CST
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C. Russell, former Chief Executive Officer of Shire plc, has been appointed to BioTime's Board of Directors.
SHPG: 209.29 (+0.07), ITMN: 73.89 (-0.02), BTX: 3.62 (+0.11)
Additions/deletions from Nasdaq's Q-50 Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 6:54AM CST
GLNG: 36.67 (+1.15), MXIM: 31.97 (+0.31), ODFL: 79.34 (+0.71), NUAN: 14.37 (-0.09), UTHR: 130.22 (+2.40), FSLR: 43.67 (-0.39), QQQ: 104.30 (+0.09), ALNY: 93.52 (+0.97), SCTY: 56.76 (+0.92), SHPG: 209.29 (+0.07), MPEL: 24.81 (+0.20), EXPE: 89.01 (+0.09), FFIV: 135.11 (+1.17), SSYS: 81.12 (+0.24), CAR: 64.23 (-0.25), JD: 24.61 (-0.12), SPLK: 61.49 (-0.11), MELI: 127.84 (+1.30), MEOH: 46.14 (-0.14), CREE: 32.64 (+0.08)
Quarterly Changes to the NXTQ Index
GlobeNewswire - Mon Dec 15, 6:20AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the quarterly re-ranking of the NASDAQ Q-50 Index (Nasdaq:NXTQ), which will become effective prior to market open on Monday, December 22, 2014.
MXIM: 31.97 (+0.31), ODFL: 79.34 (+0.71), EA: 48.06 (+0.23), UTHR: 130.22 (+2.40), ALNY: 93.52 (+0.97), SCTY: 56.76 (+0.92), SHPG: 209.29 (+0.07), SSYS: 81.12 (+0.24), FFIV: 135.11 (+1.17), MPEL: 24.81 (+0.20), AAL: 51.43 (+1.22), CAR: 64.23 (-0.25), NWS: 14.92 (-0.07), MEOH: 46.14 (-0.14), CREE: 32.64 (+0.08), GLNG: 36.67 (+1.15), NUAN: 14.37 (-0.09), FSLR: 43.67 (-0.39), LRCX: 81.13 (-0.44), EXPE: 89.01 (+0.09), SPLK: 61.49 (-0.11), JD: 24.61 (-0.12), MELI: 127.84 (+1.30), NDAQ: 48.74 (-0.40)
Tax Inversions In The U.S.: We Gotta Get Out Of This Place
Cornell Business Review - Seeking Alpha - Sun Dec 14, 1:12PM CST
By Hunter Bosson Following a summer filled with foreign mergers, tax inversions have become the innovative and morally dubious business practice of 2014. As American firms shift their headquarters overseas, widespread claims that a continued...
MDT: 74.08 (+0.31), COV: 103.35 (+0.57), SHPG: 209.29 (+0.07), ABBV: 66.21 (+1.86), BKW: 35.50 (-1.16)
This Tiny Biotech Worries Sanofi and Shire, and Vexes GlaxoSmithKline
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 8:28AM CST
Source: Amicus Therapeutics. Doctors may soon have a new therapy to use when treating patients with Fabry Disease, a rare genetic disease that can result in kidney failure. That's because emerging biotech stock Amicus Therapeutics plans to file...
SHPG: 209.29 (+0.07), GSK: 42.85 (+0.11), SNY: 46.35 (+0.50), FOLD: 7.94 (+0.06)
What Investors Can Learn From The Portfolios Of Fund Managers
Elite Wealth Management - at Seeking Alpha - Sun Dec 14, 4:47AM CST
MU: 34.91 (-0.06), ACT: 254.20 (-1.68), C: 54.54 (+0.12), COV: 103.35 (+0.57), CVI: 39.62 (unch), AET: 89.59 (+0.14), PCLN: 1,149.78 (+2.17), FDML: 15.99 (-0.40), TWX: 85.58 (-0.20), STAY: 19.60 (-0.31), HCA: 74.89 (-0.11), EBAY: 57.10 (-0.12), MRVL: 14.33 (+0.01), SUNE: 19.50 (+0.01), SHPG: 209.29 (+0.07), GLD: 112.77 (+0.03), GM: 33.43 (-0.13), IEP: 94.25 (+0.56), GOOGL: 536.93 (-1.84), TWC: 151.15 (+0.17), AIG: 56.28 (-0.16), AAPL: 112.01 (-0.53)
Shire Updates on Pipeline at Research & Development Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 11:43AM CST
Shire plc (SHPG) hosted its research and development (R&D) Day and provided key updates on its pipeline.
VRX: 140.33 (-0.22), SHPG: 209.29 (+0.07), SCMP: 13.75 (+0.44), ABBV: 66.21 (+1.86)
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
M2 - Thu Dec 11, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/tckqjm/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC prevalent cases is plateauing in the West, globally, the number of cases is rising, a phenomenon that will contribute to market growth over the next decade. Another event affecting the market is the launch of biosimilars, given the patent expiry of the UC blockbusters, Remicade and Humira, in the US in 2018 and 2016, respectively. However, the lack of an established regulatory path for biosimilars in the US presages the slow uptake of these products in this market, which could limit their availability, and consequently, inhibit the growth of the UC market. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Overall, major barriers to the growth of the UC market include - Remicade and Humira losing patent protection in the mid-forecast - Austerity measures favoring generic prescribing - Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US Key Findings - The UC market has predominantly been driven by two TNF blockers, namely J&J's Remicade and AbbVie's Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda's Entyvio and J&J's Simponi launch in 2014, stealing market share from Humira and Remicade. - Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion's Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market. - During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals' Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer's Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis. Companies Mentioned - Johnson & Johnson - AbbVie - Takeda Pharmaceuticals - Roche - Warner Chilcott - Salix Pharmaceuticals/Santarus - Shire Pharmaceuticals - Ferring Pharmaceuticals - Pfizer - InDeX Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/tc...harmapoint
JNJ: 104.59 (+0.31), SHPG: 209.29 (+0.07), SLXP: 114.92 (-1.18)
Health Care Stocks: A Year in Review and Predictions for 2015
at The Street - Wed Dec 10, 10:38AM CST
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
ZMH: 114.11 (+0.64), ENDP: 72.10 (+0.34), BDX: 139.90 (+1.44), MDT: 74.08 (+0.31), COV: 103.35 (+0.57), ITMN: 73.89 (-0.02), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), JNJ: 104.59 (+0.31), CBST: 100.29 (-0.09), CFN: 59.18 (+0.04), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), IDIX: 24.50 (+0.05), SYK: 96.00 (-0.61), NVS: 93.91 (+0.66)